SCHEMBL26508328

SCHEMBL26508328

Cc1c(C=O)cccc1OCc1cccc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.49
F2RL3 Q96RI0 1/20 0.43
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PARP1 P09874 3/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
RORC P51449 1/20 0.40
CYP2C9 P11712 1/20 0.39
PTGER1 P34995 1/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26508079 0.91 SIRT2 (0.48) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508191 0.90 SIRT2 (0.46) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508407 0.88 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508534 0.88 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508287 0.88 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508521 0.85 SIRT2 (0.48) SIRT2F2RL3AURKARPS6KB1MRGPRX4
SCHEMBL26508213 0.84 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MRGPRX4
SCHEMBL26508220 0.82 TUBB1 (0.55) SIRT2F2RL3MRGPRX4
SCHEMBL26508315 0.82 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MEN1
SCHEMBL26508258 0.82 SIRT2 (0.47) SIRT2F2RL3AURKARPS6KB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R SIRT2 3706/4885F2RL3 298/4885AURKA 2822/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R SIRT2 3706/4885F2RL3 298/4885AURKA 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.